RightFit
RecruitingPhase not listed

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests whether tumor DNA and other cancer-related substances in blood can help predict if colon or rectal cancer will come back or spread. It is for adults with this cancer who may be able to get treatment aimed at a cure, or who recently had surgery to remove it.

This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You are age 18 or older.
  • Tests of tissue or cells confirm colorectal adenocarcinoma, a type of colon or rectal cancer.
  • Your cancer is at any stage and may be treated with the goal of a cure. If you have stage II–IV cancer and surgery left no cancer at the cut edges, you may also join before or within 3 months after surgery, before starting added treatment.
  • You can understand the study and are willing to sign a consent form.
  • You are willing to have standard follow-up checks after treatment aimed at a cure.
  • You are willing to give blood samples for research.

Who can't join

  • You have another active cancer that could affect blood test results. A condition called CHIP, which causes gene changes in blood-forming cells, does not rule you out.
  • You have another illness affecting your body or a serious disease that the study doctor believes makes this study unsuitable for you.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: 1. Age ≥ 18 years. 2. Histological/cytological confirmation of colorectal adenocarcinoma. 3. Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy. 4. Ability to understand and the willingness to sign a written informed consent document. 5. Willing to pursue standard of care surveillance post completion of curative therapies. 6. Willing to provide blood samples for correlative research. Exclusion Criteria: 1. Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and / or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible. 2. Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Study sites (10)

AZ

FL

HI

ID

NJ

TX